

available at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/peptides

Review

Is GPR39 the natural receptor of obestatin?

Dong Xiao-Ying^a, He Jin-Ming^a, Tang Sheng-Qiu^{a,*}, Li Hai-Yun^b,
Jiang Qing-Yan^b, Zou Xiao-Ting^c

^a College of Yingdong Bioengineering, Shaoguan University, Daue Avenue, Zhenjiang District, Shaoguan 512005, China

^b Laboratory of Animal Physiology and Biochemistry, College of Animal Science, South China Agriculture University, Guangzhou 510642, China

^c College of Animal Science, Zhejiang University, Hangzhou 310029, China

ARTICLE INFO

Article history:

Received 28 June 2008

Received in revised form

25 August 2008

Accepted 25 September 2008

Published online 10 October 2008

Keywords:

Diabetes

Function

GPR39

Receptor family

Structure

Obestatin

ABSTRACT

GPR39, an orphan GPCR belonging to the family of G-protein-coupled receptors, was originally identified as a receptor for obestatin. However, recently, numerous studies have demonstrated its involvement in various physiological processes. In mammals, GPR39 was found to be involved in the regulation of gastric emptying and the metabolic function. In this article, a literature and brief review of the receptor family, structure, distribution and physiological functions of GPR39 has been presented.

© 2008 Elsevier Inc. All rights reserved.

Contents

1. Introduction.....	432
2. Receptor family of GPR39.....	432
3. Structure and distribution of GPR39.....	434
3.1. Structure of the GPR39 receptor.....	434
3.2. Distribution of GPR39.....	434
4. Endogenous ligand of GPR39.....	435
4.1. Obestatin.....	435
4.2. Zinc.....	436
5. Function of GPR39.....	436
5.1. Food intake and gastric emptying.....	436
5.2. Inhibition of cell apoptosis.....	436

* Corresponding author. Tel.: +86 751 8620272.

E-mail address: tsqf_n@m_n.com (S.-Q. Tang).

0196-9781/\$ - see front matter ©

led ece with a deduced amino acid sequence 96% identical in human and rat [22]. Because of the physiological importance of the GHS-R, a search for family members was initiated and the molecular cloning was initiated. McKee et al. originally indicated that GPR38 and GPR39 had a significant amino acid sequence identity with the GHS-R, the neuropeptide Uce and the neuropeptide (Fig. 1A). Fluorescence in situ hybridization demonstrated that GPR38 and GPR39 were localized to the

chiasm and the endocrine system of the gene encoding the GHS-R and NT-R type 1 [30].

GPR38 was encoded by a single gene expressed in the hypothalamic gland, stomach, and bone marrow, and in the kidney, the ece of the melanin, which mainly regulates the endocrine (GI) function and the melanin [13]. GPR39 was expressed in the brain and the peripheral [30]. The GHS-R gene was also indicated to be the ece of the GI-acting melanin ghelin in the endocrine system of




Fig. 2 – Alignment of amino acid sequences of human, mouse, rat, chicken, quail and pig GPR39. Transmembrane regions were represented as red letters; the gene sequences are quoted from GenBank accession (nos. NM001508, NM001114392, ENSRNOG00000021586, NM001080105, EF375709, and EU669821). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)

physiological functions including the regulation of food intake, body weight, GI motility and hypothalamic and hypothalamic-meningeal [18,27,33,49]. Other members of the GPR39 receptor family are found in U. e. and ne. en. in e. . Ne. medin U and ne. en. in b. h have been implicated in the control of food intake and GI function [21,54].

3. Structure and distribution of GPR39

3.1. Structure of the GPR39 receptor

The GPR39 receptor belongs to the class of rhodopsin-like receptors including GHS-R and melanin receptor (GPR38) [20,30]. The amino acid sequence of GPR39 in human, mouse, rat, chicken and zebrafish is shown in Fig. 2.

The molecular weight of human GPR39 is 52 kDa [14]. The human GPR39 gene consists of 5 exons and 4 introns, and is located on chromosome 10p12.1 [36]. PCR analysis revealed the human GPR39 gene is flanked by two splice sites, namely GPR39-1a, encoding the full length 7-transmembrane (TM) receptor, and GPR39-1b, encoding a truncated form of GPR39-1a lacking after 5-TM (Fig. 1B) [12]. Yamamoto et al. [46,47] reported the amino acid sequence and gene structure of chicken and rat GPR39. Chicken and rat GPR39 both encode a 462-amino acid protein, with high sequence homology to human, mouse and rat GPR39. The rat GPR39 cDNA consists of 354 bp of 5'-UTR, 1484 bp of 3'-UTR and 1389 bp of coding region [47]. The chicken GPR39 gene is composed of 5 exons and 4 introns, and is located on chromosome 10p12.1, between the canonical TATA box and in the chicken GPR39 gene [46]. Recently, we determined the zebrafish GPR39 cDNA encoding a 465-amino acid protein (Fig. 2).

functional analysis of the GPR39 gene region identified HNF-1 α , HNF-4 α , and SP1 were involved in the control of GPR39 expression [12].

In mice, GPR39 mRNA expression was detected in the amygdala, thalamic cell, endocrine, nervous and pancreatic [31], in the ileal ganglion, cholelithiasis and kidney, brain in the ileum and hypothalamus by Q-PCR [19] and in the brain, endocrine, hypothalamus by in situ hybridization [24]. By RT-PCR and immunocytochemistry, Iglecia et al. [23] demonstrated GPR39 mRNA was expressed in the endocrine cell in vitro.

In birds, Yamamoto et al. demonstrated the distribution of GPR39 mRNA in chicken, where a wide range of distribution was observed with the highest level in the cholelithiasis, and moderate level in the ileum, kidney, stomach and intestine. The expression level was higher in the brain, ileum, hypothalamus, affabrics, bone marrow, and egg. Expression level of GPR39 mRNA was also measured by Q-PCR in digestive and endocrine in 1-year old

GPR39 [52]. Mochales et al. [31] and Zhang et al. [50] suggested that the high membrane concentration of binding GPR39 regulates the function of diacylglycerol in signal and adhesion. Furthermore, the study indicated that the high concentration of diacylglycerol in inhibiting histamine and anion [37], increasing membrane [6], affecting cell life span [5,53], controlling lipid metabolism [38] and increasing the concentration of fatty acid in membrane [25].

Acknowledgements

The authors gratefully acknowledge Dr. H. Kaiya (Department of Biochemistry, National Cancer Center Research Institute, Osaka, Japan) for his able comment on this paper. Thanks also extended to Mr. Claire (a student) for his able guidance and suggestions.

REFERENCES

- [1] Aaka K, Inai A, Aakaya A, Kaki I, Fujimiyama M. Obea in inhibitory activity in the anorexia and obesity in the fed state. *Am J Physiol* 2008;294:G1210–8.
- [2] Bang AS, Sile SG, Yandle TG, Richards AM, Pembe DN. Cholesterol and triglyceride levels in mammalian life and health. *J Endocrinol* 2007;192:313–23.
- [3] Basal AK, Haglund Y, Boudin J, Rothermel T, Hellmuth PM, Nalund E, et al. Little or no ability of bea in the acute high glucose modified model in the glucose-insulin axis. *BJ Pharmacol* 2007;150:58–64.
- [4] Beciani E, Raeli D, Dina F, Bologna I, Tamia L, Baccelli V, et al. Obea in inhibitory feeding behavior and glucose and insulin secretion in the rat. *J Endocrinol* 2006;29:RC16–8.
- [5] Camina JP, Camm JF, Camm JE, Diegel C, Camina A. FF. Obea in-medialed life activity of human insulinogen in the helical cell: glucose mechanim. *J Cell Physiol* 2007;211:1–9.
- [6] Calini VP, Schirh HB, Debaig SR. Obea in im- e- ment and performance and calcium physiological effects in a. *Biochem Biophys Res Commun* 2007;352:907–12.
- [7] Calan V, Gme-Ambi J, Rella F, Sila C, Gil MJ, Rangel A, et al. The bea in ece (GPR39) is expressed in human adipose and in the endocrine system. *Endocrinol* (Oxf) 2007;66:598–601.
- [8] Chael N, Alia-Pe R, Leince J, Li X, Reale-Le G. Aig A, Adir V, et al. Ommen- n “Obea in, a eide ended by the ghelin gene, e- ghelin” effect- n in the endocrine. *Science* 2007;315:766–9.
- [9] Chen CY, Chien EJ, Chang FY, Li CL, Li JC, Lee SD. Im- ac- f e i he al- bea in- n- n- nic m- il- y and e- n in- n- c- fed a- Peide_2008 [E b ahead f in].
- [10] De Sme B, Thij T, Pee TL, De e I. Effect f e i he al- bea in- n- ga- ic em- ying and in- inal- n- ac- il- y in- den- Ne- ga- en- e- l M- il_2007;19:211–7.
- [11] Dime S, Sahin M, Panlen A, Sana A, Tala D, Pina AL, et al. The n- i- i- ely ac- e- han G- e- in- c- led ece- GPR39- e- f- m cell death by inc e- ing- e- n- f- igmen- e i- helial de i- ed g- h- fac- PEDF. *J Biol Chem* 2008 [E b ahead f in].
- [12] Ege KL, Hl B, Peen PS, Hanen JB, Mlde J, Hkfel T, et al. GPR39- lice- a- ian- e- an- i- en- e gene LYPD1- e- n- and eg la- n in ga- in- e- inal- ac- , end- c- ine- anc ea- li- e- and phi- e- adi- e- i- e. *Mol Endocrinol* 2007;21:1685–98.
- [13] Feighne SD, Tan CP, McKee KK, Palha OC, Heni k DL, Peng SS, et al. Rece- f- m- il- i- den- i- ed in- he h- man ga- in- e- inal- y- em. *Science* 1999;284:2184–8.
- [14] Penier E, De en- e JE, Seidel ER. Obea in and ghelin in be- e and in- egnan- y- men. *Peide_2007;28:1937–44.*
- [15] Ce- l G, Mill- n M, Adel- n DW, Wang Y, Wang L, Ri- e J, et al. Lack f in- e ac- n- be- y- e- i- he al- in- jec- n- f- CCK and be- a- in in- he eg la- n- f- ga- ic- a- ie- y- ignaling in- den- Peide_2006;27:2811–9.
- [16] Geen BD, I- n N, Fla- PR. Di- ec- and indi- ec- effec- f be- a- in- e- i- d- n- f- d- in- ake and he eg la- n- f- gl- e- h- m- e- a- i- and in- lin- ec- e- n in mice. *Peide_2007;28(5):981–7.*
- [17] G- ZF, Ren AJ, Zheng X, Qin YW, Cheng F, Zhang J, et al. Differe- e- n- e- f- ci- c- la- ing ghelin, be- a- in le- el- f- fa- ing, e- feeding and differe- f- d- c- m- i- n- , and hei- cal- e- e- n- in a- Peide_2008;29:1247–54.
- [18] Haya- hida T, M- akami K, M- gi K, Ni- hiha a M, Naka a- M, M- ndal M, et al. Ghelin in- m- e- ic- animal- di- ib- n- in- mach and i- e- ble- le. *Anim Endocrinol* 2001;21:17–24.
- [19] Hl B, Ege- d KL, Schild E, Vickle SP, Chee- ham S, Gelach LO, et al. GPR39- ignaling i- im- la- ed by- inc- n- b- m- by- be- a- in. *Endocrinol* 2007;148:13–20.
- [20] Hl B, Hlida ND, Bach A, Elling CE, G- HM, Sch- a- TW. Gmm- n- c- al- ba- i- f- n- i- i- e- ac- i- y- f- he ghelin ece- family. *J Biol Chem* 2004;279:53806–17.
- [21] H- a- d AD, Wang R, Peng SS, Mellin TN, Sack A, Gan XM, et al. Iden- i- ca- n- f- ece- f- ne- medin U and i- le in feeding. *Nature* 2000;406:70–4.
- [22] H- a- d AD, Feighne SD, C- ly DF, A- ena JP, Libe a- PA, Renbl- m CL, et al. A- ece- f- i- i- a- y- and h- h- alam- ha- f- nc- n- in g- h- h- m- ne- elea- e. *Science* 1996;273:974–7.
- [23] Igle- ia- MJ, Salgad- A, Pinei- R, R- dir- BK, O- e- MF, G- i- ian L, et al. Lack f effec- f- he ghelin gene- de i- ed e- i- d- be- a- in- n- ca- d- m- y- c- e- i- abili- y- and me- ab- li- m. *J Endocrinol* 2007;30:470–6.
- [24] Jack- n VR, N- hacke HP, Ci- elli O. GPR39- ece- f- e- e- n in- he m- e- b- ain. *Nature* 2006;17:813–6.
- [25] K- i- ca M, Zabi- ka M, P- i- I, Jank- y- ka A, Kaki I, K- a- a- a A, et al. Obea in- im- la- e- he- ec- e- n- f- anc ea- i- c- i- ce- n- yme- h- gh- a- gal- a- h- y- a- in- ana- he- i- ed a- - elimina- y- e- l- . *J Physiol Pharmacol* 2007;58(S- l- 3):123–30.
- [26] K- bel P, Wi- e- AS, S- engel A, G- ebel M, Banne- N, Ce- l G, et al. Pe- i- he al- be- a- in ha- m- effec- n- feeding beha- r- and b- ain- f- e- e- n in- den- Peide_2008;29:1018–27.
- [27] K- jima M, H- da H, Da- e Y, Naka a- M, Ma- d- H, Kang- a- K. Ghelin i- a- g- h- h- m- ne- elea- ing ac- yla- ed e- i- d- f- m- mach. *Nature* 1999;402:656–60.
- [28] Laga- d GJ, Y- ng A, Acena A. Obea in- ed ce- f- d- in- ake and e- e- b- dy- weigh- gain in- den- . *Biochem Biophys Res Commun* 2007;357:264–9.
- [29] La- e- E, Land- y B, A- ken- L, Sch- f- L, L- y- en W. Obea in- e- m- ac- i- a- e- han G- e- in- c- led ece- GPR39. *Biochem Biophys Res Commun* 2006;351:21–5.
- [30] McKee KK, Tan CP, Palha OC, Li J, Feighne SD, Heni k DL, et al. C- ning and cha- ac- e i- a- n- f- y- h- man G- e- in- c- led ece- f- gene- (GPR38 and GPR39) el- a- ed f- he g- h- h- m- ne- ec- e- a- g- e- and ne- e- n- in- ece- f- . *Genomic* 1997;46:426–34.
- [31] M- echa- D, De- e- e I, M- ea- B, de Sme- B, G- i- I, H- ken- L, et al. Al- e- ed ga- in- e- inal- and me- ab- li- f- nc- n in- he GPR39- be- a- in- ece- f- -kr- ck- m- e- . *Genomic* 2006;131:1131–41.
- [32] M- ndal MS, T- hinai K, Uerr- H, K- hinaka K, Naka a- M. Cha- ac- e i- a- n- f- be- a- in in- a- and h- man- mach

- and la_{ma} and i_{lack} of fac_{ile} effec_{tion} feeding beha_{vi}or in *den*. *J Endocrinol* 2008;198:339-46.
- [33] Naka_{ama} M, Ma_{akami} N, Da_{ei} Y, Ko_{jima} K, Ma_{chi} H, Kanga_{ya} K. e_{al}. A_{role} of gh_{relin} in_{the} cen_{tral} eg_{ulation} of feeding. *Nat* 2001;409:194-8.
- [34] Ng_{ei} a_R, P_{ge} P, T_a S, A_{rol} M, Mi_{chell} S, M_{ori} A, Pe_e-Til_e D, e_{al}. Effec_{tion} of be_{havioral} ene_{rgy} balance and g_{rowth} h_{ormone} ec_{onomy} in *den*. *Endocrinology* 2007;148:21-6.
- [35] Ng_{ei} a_R, T_a S, Mi_{chell} SE, Ray_{ne} DV, A_{che} ZA, Dieg_e C, e_{al}. Reg_{ulation} of g_{rowth} h_{ormone} ec_{onomy} ag_{ing} e_{ffects} gene_{expression} in_{the} ac_{ute} n_{euro}clei_{of} he_{althy} in_{and} gh_{relin}. *Diabetes* 2004;53:2552-8.
- [36] Ng_{ei} a_R, T_{ch} M. Se_a a_{role} of c_{on}joined h_{ormone} yield_{able} i_n al_l. *Science* 2005;310:985-6.
- [37] Sam_{son} WK, Whi_{te} MM, P_{ice} C, Fe_g n_{AV}. Obe_{esity} in ac_{tion} b_{ehavioral} inhi_{bit} hi_{gh}. *Am J Physiol Regl Ineg C* 2007;292:R637-43.
- [38] Sam_{son} WK, Y_{en} GL, Chang JK, Fe_g n_{AV}. Obe_{esity} in inhi_{bit} a_{ction} in_{the} ec_{onomy} e_{vidence} f_{or} a_{hy}po_{thetical} ac_{tion} in_{the} c_{on}l_{of} id_{entity} me_{chanism}. *J Endocrinol* 2008;196:559-64.
- [39] Se_{ane} LM, Al_{Ma}adi O, Pa_u Y, Pag_u U, Ca_{an} e_a FF. Cen_{tral} be_{havioral} admini_{stration} a_{ction} of e_{nter}o_{crine} dif_{ferential} ei_{ther} n_{euro}ane_{sthesia} gh_{relin}-ind_{uced} f_{ood} in_{ake} in_{the} a_{ction}. *J Endocrinol In* 2006;29:RC13-5.
- [40] Sibilia V, B_eciani E, La_{ada} N, Ra_ei D, I_{ca}elli V, De L_{ca} V, e_{al}. In_{action} eb_{ehavioral} en_{ic} la_{ction} and ch_{ronic} admini_{stration} a_{ction} of be_{havioral} in_{minimally} affec_{tion} f_{ood} in_{ake} b_{ehavioral} weigh_t gain in_{the} a_{ction}. *J Endocrinol In* 2006;29:RC31-4.
- [41] Smi_h RG, Pal_{ya} OC, Feigh_{ne} SD, Tan CP, McKee KK, H_{eni} k DL, e_{al}. G_{rowth} h_{ormone} elea_{vation} b_{alance}: y_{ield} and hei_{ght} e_{ffects} h_{ormone} Re_{view 1999;51(S_{uppl} 3):1-8.}
- [42] S_{ch}hann L, H_{il} B, Sch_{wa} TW. M_{olecular} la_{ction} mechani_{sm} of Zn(2+) ag_{onist} in_{the} e_{nter}o_{crine} cell la_{ction} main_{tenance} of GPR39. *FEBS Lett* 2008;582:2583-8.
- [43] T_{em}blay F, Pe_{ea} l M, Klaman LD, T_{bin} JF, Smi_h E, Gimer_{RE}. N_{euro}mal f_{ood} in_{ake} and b_{ehavioral} weigh_t in_{mice} lacking_{the} G_{protein}-c_{oupled} e_{ffects} GPR39. *Endocrinology* 2007;148:501-6.
- [44] Unnia_n S, S_{eck} M, Kieffe_{TJ}. Me_{tabolic} effec_{tion} of ch_{ronic} be_{havioral} in_{inf} in_{the} a_{ction}. *Peptide* 2008;29:1354-61.
- [45] Yamam_{oto} D, I_{ke}hi a N, Dai_R, He_{ning} ya_{EH}, T_a K, Takaha_{hi} K, e_{al}. Nei_{gh} in_{the} a_{ction} in_{action} eb_{ehavioral} en_{ic} la_{ction} admini_{stration} a_{ction} of be_{havioral} in_{the} ec_{onomy} e_{vidence} f_{or} GH, PRL, TSH and ACTH in_{the} a_{ction}. *Regl Pe* 2007;138:141-4.
- [46] Yamam_{oto} I, N_{ma} M, Sakag_{uchi} Y, T_{hima} N, Tanaka M. M_{olecular} la_{ction} a_{ction} of e_{vidence} and e_{vidence} of chicken GPR39. *Gen C* 2007;151:128-34.
- [47] Yamam_{oto} I, Sakag_{uchi} Y, N_{ma} M, T_{kada} A, T_{hima} N, Tanaka M. P_{rima} y_{ield} and i_n e_{vidence} of GPR39 me_{chanism} in_{the} c_{leic} acid in_{the} Ja_{ane} ail, *Coturni japonica*. *Pl Sci* 2007;86:2472-6.
- [48] Ya_{da} S, Mi_{ya} aki T, M_{echika} K, Yama_{hi} a M, Ikeda Y, Kami_{ro} A. I_{nter}la_{ction} of Zn²⁺ a_{ction} end_{ogenous} ag_{onist} of GPR39 f_{or} me_{chanism} in_{the} m_{echanism}. *J Rece_{ption} Signal T and c* Re_{view 2007;27:235-46.}
- [49] Y_{hi}hi a F, Ko_{jima} M, H_{da} H, Naka_{ama} M, Kanga_{ya} K. Gh_{relin}: a_{role} el_{ect}ide f_{or} g_{rowth} h_{ormone} elea_{vation} and feeding eg_{ulation} in_{the} C_{on} in_{the} Clin N_{euro} Me_{tab} Ca_{tion} 2002;5:391-5.
- [50] Zhang JV, Jah_H L_W, Klein C, Van_K len K, Ve_D nck L, e_{al}. Obe_{esity} in_{the} c_{on}l_{of} e_{vidence} f_{or} e_{vidence} in_{the} ga_l in_{the} e_{vidence} and ad_{ditional} e_{vidence} and he_{media} f_{or} le_{vel} of G_{protein}-c_{oupled} e_{vidence} f_{or} GPR39. *Mol Endocrinol* 2008;22:1464-75.
- [51] Zhang JV, Klein C, Ren PG, Ka_S, D_{nick} LV, M_{echa} D, e_{al}. Re_{duction} of c_{on}mmen_{tion} Obe_{esity} in_{the} a_{ction} ide_{entity} en_{coded} by_{the} gh_{relin} gene_{expression} in_{the} gh_{relin} effec_{tion} f_{ood} in_{ake}. *Science* 2007;315:766.
- [52] Zhang JV, Ren PG, A_{lian}-K_e chme_O, L_W, Ra_{ch} R, Klein C, e_{al}. A_{ction} ide_{entity} en_{coded} by_{the} gh_{relin} gene_{expression} in_{the} gh_{relin} effec_{tion} f_{ood} in_{ake}. *Science* 2005;310:996-9.
- [53] Zhang Z, Z_{DJ}, Chen Y, Wang M, W_J, G_{ZF}. Obe_{esity} in inhi_{bit} _{of} life a_{ction} and diffe_{rential} a_{ction} of 3T3-L1 eadi_{cy} e_{vidence}. *Acad J Sec_{ond} Mil Med Uni* 2007;28:929-32.
- [54] Zha_D, P_h laki C. Effec_{tion} of NT_{in} ga_l in_{the} e_{vidence} in_{the} m_{echanism} and ec_{onomy} e_{vidence}, and _{of} le_{vel} in_{the} e_{vidence} in_{the} amma_{tion}. *Peptide* 2006;27:2434-44.</